Avineuro Reports Positive Phase 2a Clinical Proof of Concept Trial Results on AVN-211, Potent Small Molecule for Treatment of Schizophrenia
2/22/2011 9:09:44 AM
More...
|
Avineuro Reports Positive Phase I Clinical Trial Results On AVN-322, Potent Small Molecule For Treatment Of Alzheimer’s Disease
3/1/2010 11:48:34 AM
More...
|
Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-101, Potent Small Molecule For Treatment Of Alzheimer's Disease And Anxiety
2/2/2010 12:11:24 PM
More...
|
Avineuro Reports Positive Phase I Clinical Trial Results on AVN-101, Potent Small Molecule for Treatment of Alzheimer’s Disease
10/27/2009 12:20:35 PM
More...
|
Clinical Development Milestones Achieved for Avineuro CNS Collaboration with ChemDiv, Inc.
9/16/2009 11:02:16 AM
More...
|
Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-397, Potent Small Molecule For Treatment Of Anxiety And Alzheimer's Disease
6/23/2009 11:50:25 AM
More...
|
Avineuro Announces Beginning Of Phase I Clinical Studies Of AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease
6/16/2009 11:48:07 AM
More...
|
Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-211, Potent Small Molecule For Treatment Of Schizophrenia
6/10/2009 8:18:26 AM
More...
|
Avineuro Reports Positive Phase I Clinical Trial Results On AVN-211, Potent Small Molecule For Treatment Of Schizophrenia
5/19/2009 1:30:24 PM
More...
|
Avineuro Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimer's Disease
4/7/2009 9:12:52 AM
More...
|
|